Tags

Type your tag names separated by a space and hit enter

Sildenafil (Viagra) and ophthalmology.
Surv Ophthalmol. 1999 Sep-Oct; 44(2):153-62.SO

Abstract

Sildenafil citrate (Viagra) is a new oral medication that inhibits phosphodiesterase-5 (PDE5) in the corpus cavernosum to facilitate penile erection for the treatment of male impotence. The drug also has a mild inhibitory effect on PDE6, which controls the level of cyclic guanosine monophosphate in the retina, and it may cause a perception of bluish haze or increased light sensitivity in some patients. Long-term retinal damage has not been reported, but long-term electroretinographic studies have not been performed. Sildenafil causes a mild lowering of blood pressure and is absolutely contraindicated in patients taking any form of nitrate medication. A number of cardiovascular deaths and retinal vascular events in patients taking sildenafil have been reported, but so far the rate of these complications does not exceed expectation for an elderly population. Ophthalmologists should alert patients to the ocular side effects and potential risks of this new drug until further clinical experience has been obtained.

Authors+Show Affiliations

Department of Ophthalmology, Stanford University School of Medicine, California 94305-5308, USA.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

10541153

Citation

Marmor, M F., and R Kessler. "Sildenafil (Viagra) and Ophthalmology." Survey of Ophthalmology, vol. 44, no. 2, 1999, pp. 153-62.
Marmor MF, Kessler R. Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol. 1999;44(2):153-62.
Marmor, M. F., & Kessler, R. (1999). Sildenafil (Viagra) and ophthalmology. Survey of Ophthalmology, 44(2), 153-62.
Marmor MF, Kessler R. Sildenafil (Viagra) and Ophthalmology. Surv Ophthalmol. 1999 Sep-Oct;44(2):153-62. PubMed PMID: 10541153.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sildenafil (Viagra) and ophthalmology. AU - Marmor,M F, AU - Kessler,R, PY - 1999/12/14/pubmed PY - 1999/12/14/medline PY - 1999/12/14/entrez SP - 153 EP - 62 JF - Survey of ophthalmology JO - Surv Ophthalmol VL - 44 IS - 2 N2 - Sildenafil citrate (Viagra) is a new oral medication that inhibits phosphodiesterase-5 (PDE5) in the corpus cavernosum to facilitate penile erection for the treatment of male impotence. The drug also has a mild inhibitory effect on PDE6, which controls the level of cyclic guanosine monophosphate in the retina, and it may cause a perception of bluish haze or increased light sensitivity in some patients. Long-term retinal damage has not been reported, but long-term electroretinographic studies have not been performed. Sildenafil causes a mild lowering of blood pressure and is absolutely contraindicated in patients taking any form of nitrate medication. A number of cardiovascular deaths and retinal vascular events in patients taking sildenafil have been reported, but so far the rate of these complications does not exceed expectation for an elderly population. Ophthalmologists should alert patients to the ocular side effects and potential risks of this new drug until further clinical experience has been obtained. SN - 0039-6257 UR - https://www.unboundmedicine.com/medline/citation/10541153/Sildenafil__Viagra__and_ophthalmology_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S003962579900079X DB - PRIME DP - Unbound Medicine ER -